Partial Purification and Characterization of the Mode of Action of Enterocin S37: A Bacteriocin Produced by <i>Enterococcus faecalis</i> S37 Isolated from Poultry Feces

Belguesmia, Y.; Choiset,  Y.; Prévost, H.; Dalgalarrondo, M.; Chobert, J.-M.; Drider, D.

doi:https://doi.org/10.1155/2010/986460

Journal of Environmental and Public Health

On this page

Abstract Introduction Materials and Methods Results Discussion Abbreviations Acknowledgments References Copyright Related Articles

Research Article | Open Access

Volume 2010 | Article ID 986460 | https://doi.org/10.1155/2010/986460

Partial Purification and Characterization of the Mode of Action of Enterocin S37: A Bacteriocin Produced by Enterococcus faecalis S37 Isolated from Poultry Feces

Y. Belguesmia,¹ Y. Choiset,²H. Prévost,¹M. Dalgalarrondo,²J.-M. Chobert,²and D. Drider^1,3

Academic Editor: David O. Carpenter

Received12 May 2010

Accepted22 Jun 2010

Published02 Aug 2010

Abstract

The aim of this research was to purify and characterize the mode of action of enterocin S37, a bacteriocin produced by Enterococcus faecalis S37, a strain recently isolated from the chicken feces. Enterocin S37 has a molecular weight comprised between 4 and 5 kDa. It remained active after 1 h at and at pH values ranging from 4.0 to 9.0. Furthermore, cell-free supernatant of Enterococcus faecalis S37 and purified enterocin S37 were active against Gram-positive bacteria including Listeria monocytogenes EGDe, L. innocua F, Enterococcus faecalis JH2-2, and Lactobacillus brevis F145. The purification of enterocin S37 was performed by ammonium sulfate precipitation followed up by hydrophobic-interaction chromatography procedures. Treatment of enterocin S37 with proteinase K, -chymotrypsin, and papain confirmed its proteinaceous nature, while its treatment with lysozyme and lipase resulted in no alteration of activity. Enterocin S37 is hydrophobic, anti-Listeria and likely acting by depletion of intracellular K⁺ ions upon action on channels. This study contributed to gain more insights into the mode of action of enterocins.

1. Introduction

Bacteriocins are ribosomally synthesized antimicrobial peptides produced by bacteria that deserve considerable interest for their use as natural and nontoxic food preservatives as well as for their potential use in human and veterinary applications, and in the animal production field [1]. In 1976 Tagg et al. defined bacteriocins as proteinaceous compounds that kill closely related bacteria but it is now recognized that bacteriocins can also have activity across genera (broad spectrum) [2–4]. The antimicrobial sensitivity of a target strain to any given bacteriocin may depend on the ecological conditions under which it is grown as variations in salt concentration, pH, the presence of membrane disrupting molecules, or inducing cultures, and a large number of other environmental parameters can have a significant impact [5, 6]. The classification of Gram-positive bacteriocins is rendered difficult because of their heterogeneity and thus, as the number of Gram-positive bacteriocins identified has continued to increase, classification schemes have had to continuously evolve [1].

Klaenhammer [8] suggested four classes of bacteriocins including class I or lantibiotics, which are small membrane-active peptides ( 5 kDa) containing the unusual amino acids lanthionine or β-methyl lanthionine (hence the name lantibiotics) and dehydrated residues. Nisin is the most characterized of the class I bacteriocins. Class II is defined as small heat-stable nonlanthionine containing membrane active peptides characterized by the presence of a Gly-Gly processing site in the bacteriocins precursor, the presence of amphiphilic helices with varying amounts of hydrophobicity and moderate to high-heat stability. These were further subdivided into three subgroups named subclass IIa, which are Listeria active peptides and YGNGV box in the N-terminal [9]; subclass IIb: poration complexes consisting of two proteinaceous peptides for activity [10] and subclass IIc, which contains thiol activated peptides requiring reduced cysteyl residues for activity [8]. Class III is large heat labile proteins, often with enzymatic activity and finally class IV, which is composed of complex proteins. However, recent classification reported only three major classes [11].

Many Enterococcus strains from various ecosystems were characterized as antagonists of broad range of foodborne pathogens [12, 13]. The bacteriocins produced by enterococcal strains displayed heterogeneous structures and differences in their mode of action [14]. Most of bacteriocin Producers enterococcal strains were isolated not only from different types of food, but also from broilers [2, 4] and animal secretions [15]. As reported in the literature, some of these bacteriocins exhibited high activities against broad spectrum of bacteria including Gram-positive bacteria, like Staphylococcus and Streptococcus and Gram-negative bacteria like Campylobacter or Salmonella, strains of medical interest [2, 4, 16]. The ability to produce such a biocompound may play a role in providing an ecological advantage on nonbacteriocin producer strains. Previously, we have isolated a strain of E. faecalis from chicken drop [7] which appeared to be a bacteriocin producer. In this work, we have undertaken the purification and characterization of the mode of action of this peptide named enterocin S37.

2. Materials and Methods

2.1. Bacteriocin Producer Strain

E. faecalis S37 was isolated from poultry feces collected in a French farm located in Ancenis (West of France) [7]. E. faecalis S37 was identified by sequencing whole 16S rRNA gene [7]. E. faecalis S37 showed in first instance an antagonism directed against strains belonging to Listeria and Campylobacter species [7].

2.2. Antimicrobial Activity

The antibacterial activity of enterocin S37 was assessed against the Gram-negative and Gram-positive bacteria listed in Table 1. The cell-free supernatant (CFS) and partially purified enterocin S37, by ammonium sulfate precipitation and two successive reversed phase-high performance liquid chromatography (RP-HPLC) steps, were used in order to assess the antagonism toward the target strains listed in Table 1. E. faecalis S37, E. faecalis JH2-2, Lactobacillus brevis F1.114, Lb. bulgaricus 340, Lb. brevis F145, Pseudomonas sp. 131, Escherichia coli CIP 76.24, Salmonella montevideo, Sal. enterica serotype enteritidis CIP 81.3, Staphylococcus epidermidis CIP 68.21, Bacillus cereus CIP 78.3,and Leuconostoc mesenteroides subsp. mesenteroides DSM 20240 were grown on Brain Heart Infusion broth (BHI) medium (AES, Bruz France), whilst L. monocytogenes EGDe and L. innocua F were grown on Elliker medium (AES). Campylobacter jejuni NCTC 11168 was grown in Brucella medium (AES).

The antibacterial activity was measured by the well known agar diffusion test [12]. For this purpose, 100 L from overnight culture of targeted strains was added to 20 ml of Elliker or BHI soft agar medium already containing 0.8% (w/v) of agar (Biokar diagnostics, Beauvais, France). Wells were performed in solid agar and 50 l of each sample tested was poured into the wells. The Petri dishes were left at room temperature, in sterile conditions, for 1 h before incubation for 18 h at adequate temperature according to the target strain to be tested. After this period of incubation, the antibacterial activity was detected by observing the inhibition zones around the well containing the CFS. It should be noted that supernatant was obtained by centrifuging at 15000 g during 30 min at C, an overnight culture of E. faecalis grown at C for 18 to 24 h, on de Man Rogosa Sharpe (MRS) medium [17] (AES). The CFS was neutralized by addition of 1 N NaOH and filtered through 0.2 m membrane (Sartorius, Goettingen, Germany).

Arbitrary Unit (AU) was calculated as described by Batdorj et al. [12]. Serial two fold dilution of samples was performed with phosphate buffer (25 mM K₂HPO₄, 25 mM KH₂PO₄, pH 7) filtered through 0.2 m membrane (Sartorius). These samples were tested by agar diffusion test on L. monocytogenes EGDe strain, as described previously. One arbitrary unit was defined as the reciprocal of the lowest dilution that did not show growth of the target strain.

2.3. Bacteriocin Purification

The CFS neutralized and filtered (400 ml) was precipitated with ammonium sulfate to 80% saturated solution. Three distinct fractions were recovered and were resuspended in 40 ml of phosphate buffer (25 mM K₂HPO₄, 25 mM KH₂PO₄, pH 7); the active one was applied onto RP-HPLC column (ATOLL 15 MP3; 250 mm × 10 mm Interchim, Montluçon, France) previously equilibrated with solvent A (0.05%, v/v, trifluoroacetic acid [TFA]). Elution was performed by using a gradient from 0% solvent B (0.045%, v/v, TFA, 80% acetonitrile) to 100% solvent B in 45 min. The flow rate was adjusted to 3 ml.min^-1 and the absorbance was recorded at 220 and 280 nm. Fractions of 10 ml were collected and tested for their antibacterial activity. The acetonitrile was removed from the active fractions by Speed-Vac concentrator (SC110A, Savant) and pH was adjusted to 6.8 using phosphate buffer (50 mM; pH 7). The active fractions were pooled and the purification of the bacteriocin was continued by RP-HPLC on a Waters Alliance apparatus with Millennium software (Millford, MA, USA). Concentrated bacteriocin (80 l) was injected into an analytical C₁₈ column (Symmetry 300; 5 m; Spherical 300 Å; 150 × 4.6 mm, Waters, Guyancourt, France) equilibrated in 0% solvent C (0.045% TFA in H₂O) and 50% solvent D (80% acetonitrile, 20% H₂O, 0.05% TFA). The elution was performed with a linear gradient from 30% to 100% solvent D in 30 min. The flow rate was adjusted to 0.8 ml min^-1. The eluted peaks were detected by spectrophotometry measuring the absorbance between 210 and 300 nm with a photo diode array detector (PDA 996; Waters) and collected manually. The fractions were then concentrated in a Speed-Vac concentrator.

2.4. Effect of Enzymes, pH and Heat Treatment on Antibacterial Activity of Bacteriocin

The effect of -chymotrypsin (1 ), papain (1 ), proteinase K (0.5 mg/ml^-1), lysozyme (2 ), and lipase (1 ) (all enzymes were from Sigma-Aldrich, Germany) on the antibacterial activity of enterocin S37 was checked by the agar diffusion assay as described by Batdorj et al. [12]. CFS was treated with the aforementioned enzymes for 1 h at C. The pH stability was studied as described by Line et al. [2]. Thus, samples (CFS) of 10 ml were adjusted to pH values ranging from 3 to 10 with 1 N HCl or 1 N NaOH. The obtained fractions were incubated for 2 h at C. After this period of incubation, the antibacterial activity of each treated sample was determined by the agar well diffusion assay [12]. The stability of enterocin S37 was studied at high temperature by heating 100 l of supernatant at C for 15 min, C for 1 h and C for 15 min. After cooling in ice, each sample was tested for its antagonism by agar well diffusion assay [12].

2.5. Sodium Dodecyl Sulfate (SDS) Polyacrylamide Gel Electrophoresis (PAGE)

In order to determine the apparent molecular mass of enterocin S37, the SDS-PAGE gel was cut into two parts. The part of the gel containing the molecular markers and the samples were stained by silver nitrate coloration method [18], and the remaining part, containing only samples, was extensively washed with regularly replaced sterile MilliQ water. Second part of the gel was used for direct detection of antimicrobial activity by overlaying with soft agar (0.8%) seeded with indicator strain L. monocytogenes EGDe and incubated overnight atC.

2.6. Development of Bacteriocin-Resistant Variants to Enterocin S37

Resistant variants to enterocin S37 were developed by stepwise culture of strain of L. monocytogenes EGDe at C in tryptic soy broth (Biokar diagnostics) supplemented with 0.6% (w/v) yeast extract (Organotechnie SA, La Courneuve, France) and called TSYE broth (TSYEB). Enterocin S37 was added at 2- 4- 6- 8- and 10-fold the minimal inhibitory concentration (MIC). The MIC was determined for L. monocytogenes EGDe according to Naghmouchi et al. [19] using microplate reader ELx808 (BioTek Instruments, Bad Friedrichshall, Germany). The stability of the resistant variants was checked over 50 generations. After growth of 50 generations in TSYEB at C, the strain was inoculated in the TSYEB containing enterocin S37 at 10-fold MIC.

2.7. Effect of K⁺ Channel Modulators

L. monocytogenes EGDe and its bacteriocin-resistant variant were grown at C for 24 h in TSYEB in the presence of enterocin S37 at 5 and K⁺ channel modulators such as pinacidil (Pi) at 10 , cromakalim (Cro) at 10 and glipizide (Gli) at 10 Combination of enterocin S37 with each of K⁺ channel modulator was also realized in similar conditions. All these K⁺ channel modulators were obtained from Sigma-Aldrich (Germany). Growth was monitored by measuring the optical density at 595 nm (OD₅₉₅) of 250 l of freshly inoculated medium placed into microplate wells [19].

The inhibitory activity (IA) of enterocin S37 in presence or absence of each K⁺ channel modulator was calculated as described by Naghmouchi et al. [19]. Clearly, a percentage of IA = 100 – 100 (OD₅₉₅(x)/OD₅₉₅(i)) (during exponential growth). The value (x) was the culture containing inhibitor and (i) was the uninhibited control culture. Data were expressed as the percent change in IA obtained with the enterocin S37/K⁺ channel modulator.

3. Results

3.1. Spectrum of Activity of Enterocin S37

CFS of E. faecalis S37 displayed activities against E. faecalis JH2-2, Lb. brevis F1.114, Lb. brevis F145, L. monocytogenes EGDe, and L. innocua F. However, none antibacterial activity was detected against the remaining strains listed in Table 1. Surprisingly, the anti-Campylobacter activity previously observed [7] was not recovered in this study arguing on instability trait (Table 1). Furthermore, the activity observed against strains of Enterococcus genus is interesting in order to generate novel knowledge on immunity proteins and cross-resistance within this genus.

3.2. Effects of Enzymatic and Physicochemical Treatments on Enterocin S37 Activity

CFS of E. faecalis S37 displayed activity against the target strains E. faecalis JH2-2, Lb. brevis F1.114, Lb. brevis F145, L. monocytogenes EGDe and L. innocua F even after treatments with lipase (1 mg) and lysozyme (2 mg). The antibacterial activity observed upon lipase and lysozyme treatments was similar to that observed with the untreated supernatant used as positive controls. However, treatment with proteolytic enzymes, such as -chymotrypsin, papain, and proteinase K resulted in the loss of the bacteriocin activity (Table 2). The stability of antibacterial activity of enterocin S37 remained intact after heating treatments (C for 1 h and C for 15 min) and at pH values ranging from 4 to 9 (Table 2). Attempts to reduce putative disulfide bridge (s) of enterocin S37 were performed with dithiothreitol (Sigma, Germany); the experiment was not conclusive because of toxicity of this compound, even at low concentrations, towards the target strains.

3.3. Purification of Enterocin S37

The bacteriocin was purified by a three-step method including ammonium sulfate precipitation and two RP-HPLC. The first stage consisted in an ammonium sulfate precipitation at 80%, which allowed concentrating the active fraction 10-fold (v/v); subsequently, the active fraction was passed through two successive RP-HPLC columns. Active fractions (those exhibiting antibacterial activity) were eluted at 60% of elution buffer containing 80% acetonitrile, 20% H₂O, and 0.05% TFA. The purity of each active fraction collected after each step was checked on SDS-PAGE (Table 3, Figure 1).

Figure 1

Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Tricine-SDS-PAGE). (a) Silver-stained gel. Lane 1: molecular weights markers; lane 2: culture supernatant of E. faecalis S37; lane 3: heat and filtered supernatant culture of E. faecalis S37; lane 4: active fraction collected after ammonium sulfate precipitation; lane 5: active peak obtained after first RP-HPLC; lane 6: active peak obtained after second RP-HPLC. (b) The gel was overlaid with L. monocytogenes EGDe to determine the antimicrobial activity of the purified enterocin S37; lane 7: active peak obtained after first RP-HPLC; lane 8: active peak obtained after second RP-HPLC. (c) Agar diffusion test. Well 1: negative control (phosphate buffer); well 2: heated and filtered supernatant culture of E. faecalis S37; well 3: active fraction collected after ammonium sulfate precipitation; well 4: active peak obtained after first RP-HPLC; well 5: active peak obtained after second RP-HPLC.

Bacteriocin appeared to have a molecular weight comprised between 4 and 6 kDa (Figure 1(a)), and fitting thereof with the inhibition zone observed on SDS-PAGE (Figure 1(b)). For this purpose, the electrophoresis gel obtained after migration under nondenaturing conditions was plated directly on Elliker soft agar (0.9%) inoculated with L. monocytogenes EGDe with 1% volume transfer (v/v). The other proteins bands revealed by electrophoresis were devoid of antibacterial activity. The antimicrobial activity of each sample, obtained during purification process, was also checked by agar diffusion test on Petri dish (Figure 1(c))

3.4. Effect of K⁺ Channel Modulators

Both K⁺ channel activators (pinacidil and cromakalim) and inhibitor (glipizide) affected differently the growth of L. monocytogenes EGDe and its bacteriocin-resistant variant to enterocin S37 obtained in this research. As shown in Figure 2, the highest effect was attributed to the combination of enterocin S37 (5 ) and pinacidil (10 ). Effect of the combinations of enterocin S37 with cromakalim (10 ) and glipizide (10 ) was less important on L. monocytogenes EGDe bacteriocin-resistant variant.

4. Discussion

Enterococci are known to be widespread in nature. For most enterococcal species, the predominant habitat is the gastrointestinal tract of animals and humans where they can be found in numbers as high as 10⁸ cfu/g of feces [20]. Enterococci were found in foods of animal origin (milk, cheese, and fermented sausages), vegetables and plant materials [21]. Additionally to these natural habitats, they are implicated in nosocomial infections [22].

Many enterococci were reported to produce bacteriocins called enterocins, which are various, having great diversity in their structure, and active against numerous microorganisms, especially foodborne pathogens and against microorganisms of environmental and medical interests [2, 4, 14, 23]. Theppangna et al. [15] have studied a set of 139 strains of E. faecium and E. faecalis for their capabilities to produce enterocins and they concluded that 51% of isolates were producers of enterocins and 46% of them were able to produce more than one enterocin. The strains producing enterocins were carrying at least one structural gene coding for the most known enterocins (entA, entP, entL50AB and cylL) [15]. Other studies pointed out the importance of E. faecalis as sources of enterocins [24, 25]. Taken together, these studies indicate the distribution and importance of enterococcal strains. It should be pointed out that most of enterocins so far studied exhibited activity towards Gram-negative and Gram-positive bacteria [8]. We have undertaken isolation and characterization of enterocin named enterocin S37, which is produced by E. faecalis recently isolated from chicken feces [7]. Enterocin S37 appeared to be interesting regarding its activities against the food-borne pathogen L. monocytogenes EGDe and casually against Campylobacter jejuni NCTC 11168 (Table 1). However the anti-Campylobacter activity remained unstable and less important than that observed for other bacteriocins recently reported in the literature [2–4]. The data gathered from this study let us think of the possibility of enterocin S37 to be a class IIa bacteriocin, as (i) this peptide was anti-Listeria, (ii) has a molecular weight 10 kDa, (iii) was sensitive to proteases, and (iv) was stable at different pH and high temperatures.

Results of purification indicated that enterocin S37 was highly hydrophobic. The activity increased several folds (from 400 to 51,200 ) during the purification process (Table 3), in parallel with an increase of specific activity, which reaches 1,557.17 . This phenomenon was largely described previously as the result of removing inhibitory compounds [26–28]. The spectrum of partially purified enterocin S37 was the same to that observed with CFS, but with stronger activities (data not shown).

For the first time, the effect of K⁺ channel modulators on enterocin activity was revealed in this research. To this aim, we have utilized two K⁺ channel activators (cromakalim and pinacidil) and one K⁺ channel blocker (glipizide). Cromakalim was shown to act on ATP-sensitive potassium channels and caused membrane hyper polarization, pulls their membrane potential away from the threshold [29]. In the pharmacology sector, the use of cromakalim to treating hypertension was reported [29]. Pinacidil is a cyanoguanidine drug that opens ATP-sensitive potassium channels [30]. Finally, glipizide was described to affect the cell by partially blocking the K⁺ channels, reducing K⁺ conductance and causing depolarization of the membrane, which leads to Ca⁺⁺ ions influx through voltage-sensitive Ca⁺⁺ channels, causing rising of the intracellular concentrations of Ca⁺⁺ ions [31, 32]. Furthermore, the impact of cromakalim and glipizide on growth of sensitive and resistant L. monocytogenes strains was studied and resulted to be overall weak. Thus, the inhibition of wildtype (sensitive phenotype) to cromakalim and glipizide was estimated to 14.29% 1.38 and 17.14% 4.08 while the inhibition of the mutant strain (resistant phenotype) was evaluated to 4.46% 3.53 and 8.93% 1.06. Pinacidil showed high-inhibitory activity on the wildtype (86.79% 1.78) and interestingly not on the mutant strain (19.64% 4.02).

Combinations of enterocin S37 and different K⁺ channel modulators suggested an implication of enterocin S37 in a depletion of intracellular K⁺ level, by an action on channels rather than K_v channels. These data are in good agreement with those obtained formerly with nisin A, whose antibacterial activity was connected to channels with concomitant loss of all intracellular K⁺ and ATP [19]. As for enterocin AS-48 and enterocin P [33, 34], enterocin S37 is certainly responsible of uncontrolled efflux of intracellular K⁺ and affecting sensitive cells growth. The resistant variant was able to grow but was slightly affected by the combination of enterocin S37/K⁺ modulators, except for pinacidil, where the inhibitory effect has reached 49.79% 3.36, instead of 23.84% 7.73 and 24.11% 7.07 when cromakalim and glipizide were added, respectively (Figure 2).

It was also well established that many bacteriocins, including enterocins, interact with membrane lipids leading to the formation of pores and subsequently to the loss of intracellular components, resulting thereof in the cell death [35–39]. The lipid composition of membrane appeared to play an important role in the efficiency of bacteriocin activity [9, 35, 36, 38]. Enterocin S37 alone did not affect the growth of bacteriocin-resistant variant of L. monocytogenes EGDe. However, the combination of enterocin S37/K⁺ channel modulators impacted strongly the growth of resistant variant. Otherwise, the K⁺ channel modulators enhanced the inhibitory activity of enterocin S37 on sensitive strain of L. monocytogenes EGDe, with values reaching, 92.86% 5.90 and 94.29% 4.55 when enterocin S37 was combined with glipizide and pinacidil, respectively. Combination of cromakalim and enterocin S37 resulted in 84.29% 2.5 inhibition of the growth of sensitive strain; this data is equal to that obtained with enterocin S37 alone 84.21% 5.87 (Figure 2). However, in the case of resistant strain, when enterocin S37 was combined to pinacidil, a high-inhibitory activity (49.79% 3.36) was observed as compared to combinations of cromakalim + enterocin S37 (23.84% 7.73) and enterocin S37 + glipizide (24.11% 7.07) (Figure 2).

The mode of action of enterocin S37 could be triggered by potential interaction with cell membrane. The determination of aminoacid sequence of enterocin S37 is under consideration.

Abbreviations

CIP:	Collection of Institut Pasteur (Paris, France)
DSM:	DeutschSammlung von Mikroorganismenund Zellkulturen (Braunschweig, Germany)
NCTC:	National collection of type strains (London, UK).

Acknowledgments

The authors would like to thank Professor Antonio Galvez for critical reading of the paper. Y. Belguesmia is a recipient of PhD scholarship awarded by la Région des Pays de la Loire (http://www.paysdelaloire.fr/).

References

D. Drider and S. Rebuffat, Prokaryotic and Antimicrobial Peptides: from Genes to Biotechnologies, Springer, New York, NY, USA, 2010.
J. E. Line, E. A. Svetoch, and E. A. Svetoch, “Isolation and purification of enterocin E-760 with broad antimicrobial activity against Gram-positive and Gram-negative bacteria,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 3, pp. 1094–1100, 2008.
View at: Publisher Site | Google Scholar
N. J. Stern, E. A. Svetoch, and E. A. Svetoch, “Isolation of a Lactobacillus salivarius strain and purification of its bacteriocin, which is inhibitory to Campylobacter jejuni in the chicken gastrointestinal system,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 9, pp. 3111–3116, 2006.
View at: Publisher Site | Google Scholar
E. A. Svetoch, B. V. Eruslanov, and B. V. Eruslanov, “Diverse antimicrobial killing by Listeria monocytogenes E 50-52 bacteriocin,” Journal of Agricultural and Food Chemistry, vol. 56, no. 6, pp. 1942–1948, 2008.
View at: Publisher Site | Google Scholar
M. G. Gänzle, S. Weber, and W. P. Hammes, “Effect of ecological factors on the inhibitory spectrum and activity of bacteriocins,” International Journal of Food Microbiology, vol. 46, no. 3, pp. 207–217, 1999.
View at: Publisher Site | Google Scholar
B. Rojo-Bezares, Y. Sáenz, L. Navarro, M. Zarazaga, F. Ruiz-Larrea, and C. Torres, “Coculture-inducible bacteriocin activity of Lactobacillus plantarum strain J23 isolated from grape must,” Food Microbiology, vol. 24, no. 5, pp. 482–491, 2007.
View at: Publisher Site | Google Scholar
L. Nazef, Y. Belguesmia, A. Tani, H. Prévost, and D. Drider, “Identification of lactic acid bacteria from poultry feces: evidence on anti-Campylobacter and anti-Listeria activities,” Poultry Science, vol. 87, no. 2, pp. 329–334, 2008.
View at: Publisher Site | Google Scholar
T. R. Klaenhammer, “Genetics of bacteriocins produced by lactic acid bacteria,” FEMS Microbiology Reviews, vol. 12, no. 1–3, pp. 39–85, 1993.
View at: Google Scholar
D. Drider, G. Fimland, Y. Héchard, L. M. McMullen, and H. Prévost, “The continuing story of class IIa bacteriocins,” Microbiology and Molecular Biology Reviews, vol. 70, no. 2, pp. 564–582, 2006.
View at: Publisher Site | Google Scholar
L. M. Cintas, P. Casaus, H. Holo, P. E. Hernandez, I. F. Nes, and L. S. Håvarstein, “Enterocins L50A and L50B, two novel bacteriocins from Listeria monocytogenes L50, are related to staphylococcal hemolysins,” Journal of Bacteriology, vol. 180, no. 8, pp. 1988–1994, 1998.
View at: Google Scholar
P. D. Cotter, C. Hill, and R. P. Ross, “Bacteriocins: developing innate immunity for food,” Nature Reviews Microbiology, vol. 3, no. 10, pp. 777–788, 2005.
View at: Publisher Site | Google Scholar
B. Batdorj, M. Dalgalarrondo, and M. Dalgalarrondo, “Purification and characterization of two bacteriocins produced by lactic acid bacteria isolated from Mongolian airag,” Journal of Applied Microbiology, vol. 101, no. 4, pp. 837–848, 2006.
View at: Publisher Site | Google Scholar
C. Losteinkit, K. Uchiyama, S. Ochi, T. Takaoka, K. Nagahisa, and S. Shioya, “Characterization of bacteriocin N15 produced by Listeria monocytogenes N15 and cloning of the related genes,” Journal of Bioscience and Bioengineering, vol. 91, no. 4, pp. 390–395, 2001.
View at: Publisher Site | Google Scholar
C. M. A. P. Franz, M. J. Van Belkum, W. H. Holzapfel, H. Abriouel, and A. Gálvez, “Diversity of enterococcal bacteriocins and their grouping in a new classification scheme,” FEMS Microbiology Reviews, vol. 31, no. 3, pp. 293–310, 2007.
View at: Publisher Site | Google Scholar
W. Theppangna, T. Murase, N. Tokumaru, H. Chikumi, E. Shimizu, and K. Otsuki, “Screening of the enterocin genes and antimicrobial activity against pathogenic bacteria in Enterococcus strains obtained from different origins,” Journal of Veterinary Medical Science, vol. 69, no. 12, pp. 1235–1239, 2007.
View at: Publisher Site | Google Scholar
A. Galvez, M. Maqueda, and E. Valdivia, “Characterization and partial purification of a broad spectrum antibiotic AS-48 produced by Streptococcus faecalis,” Canadian Journal of Microbiology, vol. 32, no. 10, pp. 765–771, 1986.
View at: Google Scholar
J. C. De Man, M. Rogosa, and E. Sharpe, “A medium for the cultivation of Lactobacilli,” Journal of Applied Bacteriology, vol. 23, pp. 130–135, 1960.
View at: Google Scholar
H. Blum, H. Beier, and H. J. Gross, “Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels,” Electrophoresis, vol. 8, pp. 93–99, 1987.
View at: Google Scholar
K. Naghmouchi, D. Drider, R. Hammami, and I. Fliss, “Effect of antimicrobial peptides divergicin M35 and nisin A on Listeria monocytogenes LSD530 potassium channels,” Current Microbiology, vol. 56, no. 6, pp. 609–612, 2008.
View at: Publisher Site | Google Scholar
I. Kühn, A. Iversen, and A. Iversen, “Occurrence and relatedness of vancomycin-resistant enterococci in animals, humans, and the environment in different European regions,” Applied and Environmental Microbiology, vol. 71, no. 9, pp. 5383–5390, 2005.
View at: Publisher Site | Google Scholar
J. C. Giard, J. M. Laplace, A. Rince et al., “The stress proteome of Enterococcus faecalis,” Electrophoresis, vol. 22, no. 14, pp. 2947–2954, 2001.
View at: Google Scholar
W. Witte, C. Cuny, I. Klare, U. Nübel, B. Strommenger, and G. Werner, “Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens,” International Journal of Medical Microbiology, vol. 298, no. 5-6, pp. 365–377, 2008.
View at: Publisher Site | Google Scholar
A. Galvez, E. Valdivia, M. Martinez, and M. Maqueda, “Bactericidal action of peptide antibiotic AS-48 against Escherichia coli K-12,” Canadian Journal of Microbiology, vol. 35, no. 2, pp. 318–321, 1989.
View at: Google Scholar
L. De Vuyst, M. R. Foulquié Moreno, and H. Revets, “Screening for enterocins and detection of hemolysin and vancomycin resistance in enterococci of different origins,” International Journal of Food Microbiology, vol. 84, no. 3, pp. 299–318, 2003.
View at: Publisher Site | Google Scholar
R. Del Campo, C. Tenorio, R. Jiménez-Díaz, C. Rubio, R. Gómez-Lus, F. Baquero, and C. Torres, “Bacteriocin production in vancomycin-resistant and vancomycin-susceptible Enterococcus isolates of different origins,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 3, pp. 905–912, 2001.
View at: Publisher Site | Google Scholar
S. Ennahar, Y. Asou, T. Zendo, K. Sonomoto, and A. Ishizaki, “Biochemical and genetic evidence for production of enterocins A and B by Listeria monocytogenes WHE 81,” International Journal of Food Microbiology, vol. 70, no. 3, pp. 291–301, 2001.
View at: Publisher Site | Google Scholar
J. T. Henderson, A. L. Chopko, and P. D. Van Wassenaar, “Purification and primary structure of pediocin PA-1 produced by Pediococcus acidilactici PAC-1.0,” Archives of Biochemistry and Biophysics, vol. 295, no. 1, pp. 5–12, 1992.
View at: Publisher Site | Google Scholar
J. Nissen-Meyer, H. Holo, L. S. Havarstein, K. Sletten, and I. F. Nes, “A novel lactococcal bacteriocin whose activity depends on the complementary action of two peptides,” Journal of Bacteriology, vol. 174, no. 17, pp. 5686–5692, 1992.
View at: Google Scholar
B. Fioretti, C. Trequattrini, L. Sforna, A. Harper, L. Catacuzzeno, and F. Franciolini, “Cromakalim activates the K(ATP) and enhances spontaneous transient outward potassium currents in rat saphenous arterial myocytes,” Pharmacological Research, vol. 57, no. 5, pp. 398–402, 2008.
View at: Publisher Site | Google Scholar
M. Gollasch, R. Bychkov, C. Ried, F. Behrendt, S. Scholze, F. C. Luft, and H. Haller, “Pinacidil relaxes porcine and human coronary arteries by activating ATP-dependent potassium channels in smooth muscle cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 275, no. 2, pp. 681–692, 1995.
View at: Google Scholar
R. H. Foster and G. L. Plosker, “Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus,” PharmacoEconomics, vol. 18, no. 3, pp. 289–306, 2000.
View at: Google Scholar
P. K. Stys, D. A. Hubatsch, and L. L. Leppanen, “Effects of K⁺ channel blockers on the anoxic response of CNS myelinated axons,” NeuroReport, vol. 9, no. 3, pp. 447–453, 1998.
View at: Google Scholar
A. Galvez, E. Valdivia, M. Martinez, and M. Maqueda, “Effect of peptide AS-48 on Enterococcus faecalis subsp. Liquifaciens S-47,” Antimicrobial Agents and Chemotherapy, vol. 33, no. 5, pp. 641–645, 1989.
View at: Google Scholar
C. Herranz, L. M. Cintas, P. E. Hernández, G. N. Moll, and A. J. M. Driessen, “Enterocin P causes potassium ion efflux from Listeria monocytogenes T136 cells,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 3, pp. 901–904, 2001.
View at: Publisher Site | Google Scholar
S. Calvez, H. Prévost, and D. Drider, “Identification of a new molecular target of class IIa bacteriocins in Listeria monocytogenes EGDe,” Folia Microbiologica, vol. 53, no. 5, pp. 417–422, 2008.
View at: Publisher Site | Google Scholar
A. Galvez, M. Maqueda, M. Martinez-Bueno, and E. Valdivia, “Permeation of bacterial cells, permeation of cytoplasmic and artificial membrane vesicles, and channel formation on lipid bilayers by peptide antibiotic AS-48,” Journal of Bacteriology, vol. 173, no. 2, pp. 886–892, 1991.
View at: Google Scholar
G. N. Moll, W. N. Konings, and A. J. M. Driessen, “Bacteriocins: mechanism of membrane insertion and pore formation,” Antonie van Leeuwenhoek, vol. 76, no. 1–4, pp. 185–198, 1999.
View at: Publisher Site | Google Scholar
K. Naghmouchi, D. Drider, and I. Fliss, “Action of divergicin M35, a class IIa bacteriocin, on liposomes and Listeria,” Journal of Applied Microbiology, vol. 102, no. 6, pp. 1508–1517, 2007.
View at: Publisher Site | Google Scholar
K. Naghmouchi, D. Drider, E. Kheadr, C. C. Lacroix, H. Prévost, and I. Fliss, “Multiple characterizations of Listeria monocytogenes sensitive and insensitive variants to divergicin M35, a new pediocin-like bacteriocin,” Journal of Applied Microbiology, vol. 100, no. 1, pp. 29–39, 2006.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2010 Y. Belguesmia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

2680

Downloads

1373

Citations